Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Canada / NCT01468246
Active, not recruiting Observational

The Young Women's Breast Cancer Study

NCT01468246 · tracked via the Priya Life Science Canada tracker
Phase
Observational
Started
2006-11
Last updated
2026-02-03

Condition(s) studied

Breast Cancer

Study summary

The investigators are conducting a longitudinal cohort study of young women with breast cancer. The investigators identify women age 40 and younger with newly-diagnosed breast cancer from academic and community healthcare institutions. After women consent to the study, they fill-out surveys and give blood samples, and the investigators collect tissue from their breast cancer tumor after it is removed. Women are surveyed every 6 months for the first 3 years after diagnosis, then yearly thereafter for an additional 7 years (for a total follow-up of at least 10 years following diagnosis). The study investigates short and long-term disease and treatment issues, tumor biology and the relationship to patient outcomes, and psychosocial concerns at baseline and in follow-up among a cohort of young women who are newly-diagnosed with breast cancer.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
40 Years
Healthy volunteers
No
Inclusion Criteria: * Female * Diagnosis of breast cancer * Age 40 or younger at diagnosis * Informed consent obtained from patient * Ability to understand written and spoken English to the extent necessary to complete the questionnaires Exclusion Criteria: * Inability to understand written and spoken English to the extent necessary to complete the questionnaires * Absence of informed consent

Primary outcome measure(s)

Trial sites (13)

FacilityCityRegionStatus
University of Colorado Cancer Center Aurora Colorado
Beth-Israel Deaconess Medical Center Boston Massachusetts
Dana-Farber Cancer Institute Boston Massachusetts
Massachusetts General Hospital Boston Massachusetts
MGH/North Shore Cancer Center Danvers Massachusetts
Cape Cod Hospital Hyannis Massachusetts
Lowell General Hospital Lowell Massachusetts
DF/BWCC at Milford Regional Medical Center Milford Massachusetts
Newton-Wellesley Hospital Newton Massachusetts
South Shore Hospital South Weymouth Massachusetts
Mayo Clinic Rochester Minnesota
Dana-Farber/New Hampshire Oncology-Hematology Londonderry New Hampshire
Sunnybrook Health Sciences Centre Toronto Ontario

More Dana-Farber Cancer Institute trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT01468246 on ClinicalTrials.gov ↗ ← All trials in Canada